ArticleCell and tissue banking2025
Allograft valves harvesting and preservation technique for enhanced performance.
Article in Cell and tissue banking, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Allograft valves offer significant advantages in valve replacement; however, their limited availability from cadaveric or brain-dead donors presents a considerable challenge. This study aims to share our experience in harvesting and preserving Allograft valves from heart transplant recipients, addressing this shortage and streamlining the process. Allograft valves were harvested from patients who underwent heart transplants at our center from October 2007 to October 2022. After sampling of the allograft for quality control, allograft valves were cryopreserved and thawed before implantation. Allograft valves were used in 60 patients who had pulmonary valve replacement (PVR) in or after repaired Tetralogy of Fallot (TOF). Patient data were collected and statistically analyzed. The age of donors was 39.0 ± 186.0 years while the median age of recipients was 5.1 years (interquartile range, 1.5-12.1). After a median follow-up of 2.6 years (interquartile range, 1.0-6.9), the freedom from all-cause mortality was 94.0%, 89.5%, and 89.5% at 5, 10, and 15 years, respectively. Adverse clinical outcomes, occurred in 24 patients (40.0%), while freedom is 64.9%, 53.4%, and 31.7% for 5, 10, and 15 years. Allograft valves bicuspidized (odds ratio, 75.085; 95% confidence interval, 10.100-558.202, P < 0.001) and early postoperative regurgitation (odds ratio, 9.946; 95% confidence interval, 1.034-95.706, P = 0.047) were considered independent risk factors for adverse clinical outcomes. Our study presents our approach to harvesting and preserving allograft valves from heart transplant recipients, demonstrating favorable short to mid-term outcomes when utilized in allograft valves for patients with or after repaired TOF. We recommend vigilant monitoring of early postoperative regurgitation, as it may signal a poor prognosis, and we strongly advise against bicuspidized the implanted allograft valves.
Indexed as
Identifiers
40038126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.